Study of a treatment for newborns exposed to chikungunya
Part of Brain & nervous system, Infections clinical trials.
This trial tests a new treatment (PC-CHIK-V) for newborns whose mothers had chikungunya around the time of birth. The goal is to see if the treatment can prevent or reduce the infection in babies. Babies who are not treated will also be followed for comparison.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby's mother had chikungunya between 2 days before birth and 2 days after birth.
- Baby is hospitalized in a special newborn intensive care unit (Level III) in Mayotte or at the University Hospital of La Réunion.
- Treatment must be given within 12 hours of birth (if mother's infection was before delivery) or within 12 hours of diagnosis (if infection discovered after birth).
- Parents must give written permission for the baby to join the treatment group, or agree to data collection for the observation group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows pregnant women who received the VLA1553 vaccine (for chikungunya) to see how it affects them and their babies. It compares them to pregnant women who received a different vaccine approved during pregnancy.
This study tests an experimental vaccine designed to protect against chikungunya, a mosquito-borne virus that causes fever and joint pain. The trial will evaluate the vaccine's safety and immune response in healthy adults.
This study looks at how well the VLA1553 vaccine prevents chikungunya disease in parts of Brazil where the vaccine is being offered as part of a pilot program. If you live in one of those areas and have had symptoms that might be chikungunya, this study will use your health records and blood tests to check how effective the vaccine is.
This study looks at how well the chikungunya vaccine works in real life, how safe it is, and how the body's immune system responds. It is for adults who are eligible for the vaccine according to French health guidelines.
This study looks for the chikungunya virus in semen. It may help understand if the virus can be passed through sex, and why it's important for men who have been infected.
This study looks at patients with suspected, probable, or confirmed arbovirus infections (like dengue, chikungunya, or Zika) to understand what factors lead to hospitalization and how severe the illness can be. It may include adults, children, and even newborns if they might have been exposed.
Hear when a new Chikungunya Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.